---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Phase of product development"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Phase of product development. Topics: Regulatory status: Under review; BLA submitted September 2026 under the accelerated approval pathway, with a PDUFA target action date in May 2027; Commercial launch preparation; FDA acceptance of the BLA with Priority Review, November 2026; BLA submission in August 2026 and acceptance in October 2026: Form 10-Q statement; 31 further topics. 35 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Under review; BLA submitted September 2026 under the accelerated approval pathway, with a PDUFA target action date in May 2027

> “In September 2026, we announced the submission of a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (the “FDA”) for the accelerated approval of ifezuntirgene inilparvovec as well as the submission of a marketing authorization application (“MAA”) for ifezuntirgene inilparvovec to the United Kingdom’s (“UK”) Medicines and Healthcare products Regulatory Agency (“MHRA”).”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

> “The application has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

<a id="topic-2.1.1-2"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

### Commercial launch preparation

> “As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans,”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

> “The $2.4 million increase was primarily driven by a higher headcount following employee recruitment to support the potential commercial launches of ifezuntirgene inilparvovec”
> “The increase was primarily related to expenses incurred to support the preparation of a potential commercialization of ifezuntirgene inilparvovec”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.1-4"></a>

### FDA acceptance of the BLA with Priority Review, November 2026

> “On November 2 2026, we announced the FDA has accepted for review the BLA for ifezuntirgene inilparvovec, submitted under the Accelerated Approval pathway.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.1-5"></a>

### BLA submission in August 2026 and acceptance in October 2026: Form 10-Q statement

> “We submitted our BLA for ifezuntirgene inilparvovec to the FDA in August 2026 and the FDA accepted the application for review in October 2026, with a PDUFA target action date of May 1, 2027.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.1-6"></a>

### Advisory committee meeting tentatively planned

> “In its acceptance letter, the FDA stated that they are tentatively planning to discuss this application at an Advisory Committee meeting.”
> “The Company will be notified once the date and timelines have been finalized.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

<a id="topic-2.1.1-7"></a>

### Confirmatory study: alignment with the FDA on key design elements, November 2026

> “The Company and FDA have aligned on key elements of the confirmatory study design.”
> “The confirmatory trial remains a key priority, with screening anticipated to begin by year end and the study is expected to be well underway by the time of potential approval.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

<a id="topic-2.1.1-8"></a>

### BLA submission and priority review request, September 2026

> “uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for the accelerated approval of ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for the treatment of Huntington’s disease.”
> “The Company has requested priority review for the BLA. If granted, priority review would shorten the FDA review cycle to six months following the FDA’s 60-day BLA filing review period.”

Source: [uniQure press release, BLA submission (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-submission-biologics-license-application)

<a id="topic-2.1.1-9"></a>

### Four-year data not included in the marketing applications

> “The applications submitted to the FDA and MHRA predated the subsequently reported 48-month topline results, and therefore the 48-month topline results were not part of the BLA or MAA.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.1-10"></a>

### Type B meeting minutes, July 2026

> “Official meeting minutes received in July 2026 confirmed that the FDA and the Company reached alignment that a Biologics License Application (BLA) submission under the accelerated approval pathway for AMT-130, based on the existing clinical data, is reasonable.”
> “The FDA also stated that, in accordance with the FDA’s draft public guidance for accelerated approvals, the confirmatory study should be feasible to conduct within a reasonable timeline and be well underway, and potentially fully enrolled, at the time of accelerated approval.”

Source: [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and)

<a id="topic-2.1.1-11"></a>

### Type B meeting, June 2026

> “the FDA communicated that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis of a Biologics License Application (BLA) for the accelerated approval of AMT-130 in Huntington’s disease.”
> “In addition, the FDA seeks to align on the confirmatory study design prior to the BLA submission, including consideration of concurrent control on standard-of-care therapy instead of a sham procedure.”

Source: [uniQure press release, BLA plan after Type B meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons)

<a id="topic-2.1.1-12"></a>

### BLA submission timing: third quarter of 2026, June 2026, superseded in September 2026

> “The Company intends to submit the BLA in the third quarter of 2026.”

Source: [uniQure press release, BLA plan after Type B meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons)

> “Discussions with the FDA to align on the confirmatory study design and analysis are underway and the Company expects to submit a BLA in the third quarter of 2026.”

Source: [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and)

<a id="topic-2.1.1-13"></a>

### FDA position after the January 2026 Type A meeting, March 2026, superseded in June 2026

> “today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a Type A meeting held on January 30, 2026 to discuss AMT-130, an investigational gene therapy for Huntington’s disease (HD).”
> “The FDA stated that it cannot agree that data from the Phase I/II studies, compared to an external control, are sufficient to provide the primary evidence of effectiveness required to support a marketing application for AMT-130. The FDA strongly recommended uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study.”
> “uniQure intends to continue engaging with the FDA regarding Phase III development considerations and plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.”

Source: [uniQure press release, Type A meeting minutes (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-2)

<a id="topic-2.1.1-14"></a>

### Type A meeting scheduled, January 2026

> “today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, the Company’s investigational gene therapy for the treatment of Huntington’s disease.”

Source: [uniQure press release, Type A meeting scheduled (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-type-meeting-scheduled-fda)

<a id="topic-2.1.1-15"></a>

### Pre-BLA meeting minutes, December 2025

> “today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a pre-Biologics License Application (BLA) meeting held on October 29, 2025 to discuss the application for AMT-130, an investigational gene therapy for Huntington’s disease (HD).”
> “In the final meeting minutes, and consistent with uniQure’s November 3, 2025 press release, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission.”

Source: [uniQure press release, pre-BLA meeting minutes (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-1)

<a id="topic-2.1.1-16"></a>

### BLA submission timing: unclear, November 2025, superseded in June 2026

> “Though final meeting minutes have not yet been received, based on the discussions at the meeting, uniQure believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission.”
> “This is a key shift from prior communications with the FDA in multiple Type B meetings over the past year. Consequently, the timing of the BLA submission for AMT-130 is now unclear.”

Source: [uniQure press release, pre-BLA meeting feedback (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-0)

<a id="topic-2.1.1-17"></a>

### BLA submission timing: first quarter of 2026, June 2025, superseded in November 2025

> “Q1 2026: submit BLA with a request for priority review designation”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

> “We are eager to discuss the data with the FDA at our pre-BLA meeting expected later this year, with the goal of submitting a BLA in the first quarter of 2026.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-2.1.1-18"></a>

### U.S. launch timing: 2026, September 2025, superseded in November 2025

> “uniQure plans to submit a BLA in the first quarter of 2026, with anticipated U.S. launch later that year, pending approval”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

> “We believe this transaction enhances our financial flexibility to fund the potential commercial launch of AMT-130 in the United States, anticipated in 2026,”

Source: [uniQure press release, debt refinancing (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-refinancing-existing-50-million-debt-and)

<a id="topic-2.1.1-19"></a>

### FDA interactions on the statistical analysis plan, 2025

> “In the second quarter of 2025, the Company held a Type B meeting with the FDA to discuss the proposed use of external control data and the prospectively defined statistical analysis plan (SAP) in support of the planned BLA submission for AMT-130.”
> “The FDA agreed that the primary efficacy analysis for the BLA will evaluate the 3-year change in cUHDRS in high-dose AMT-130 patients compared to a propensity score-adjusted external control arm.”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

> “In July 2025, the Company submitted the final SAP to the FDA. Additionally, the Company initiated its PPQ campaign to support the planned BLA submission.”

Source: [uniQure press release, second quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2025-financial-results-and)

<a id="topic-2.1.1-20"></a>

### FDA interactions on chemistry, manufacturing and controls, 2025

> “In the first quarter of 2025, the Company held a Type B meeting with the FDA to discuss CMC requirements in support of the planned BLA submission for AMT-130. The FDA agreed that validation of the AMT-130 manufacturing process should be possible using experience and prior knowledge from the etranacogene dezaparvovec-drlb (HEMGENIX®) process, complemented with additional full-scale AMT-130 GMP batches and a single Process Performance Qualification (PPQ) batch.”
> “The FDA also agreed with the Company’s proposed drug product release testing plan, including the proposed potency assay, pending completion of qualification and specification setting activities.”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

<a id="topic-2.1.1-21"></a>

### FDA alignment on the accelerated approval pathway, December 2024, superseded in November 2025

> “As part of uniQure’s Regenerative Medicine Advanced Therapy (RMAT) Type B meeting held in late November, the FDA agreed that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway, avoiding the need for an additional pre-submission study.”
> “The FDA also agreed that cUHDRS may be used as an intermediate clinical endpoint and that reductions in neurofilament light chain (NfL) measured in cerebrospinal fluid (CSF) may serve as supportive evidence of therapeutic benefit in the application for accelerated approval.”

Source: [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated)

<a id="topic-2.1.1-22"></a>

### Designations held: current statement

> “Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. Ifezuntirgene inilparvovec also holds Fast Track designation from the FDA.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

> “In addition to the Breakthrough Therapy designation, the FDA previously granted RMAT designation, Orphan Drug designation and Fast Track designation to AMT-130.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.1-23"></a>

### Breakthrough Therapy designation: April 2025

> “In April 2025, we announced that the FDA granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington’s disease. The Breakthrough Therapy designation was supported by clinical data from the ongoing Phase I/II trials of AMT-130 for the treatment of Huntington’s disease showing the potential for meaningful slowing of disease progression.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.1-24"></a>

### Regenerative Medicine Advanced Therapy designation: May 2024

> “The FDA granted uniQure RMAT designation for AMT-130 in May 2024, stating that preliminary clinical data from the ongoing Phase I/II studies indicate AMT-130 has the potential to address unmet medical needs for the treatment of Huntington’s disease.”

Source: [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated)

> “The designation follows the FDA’s review of interim Phase I/II clinical data for AMT-130 announced in December 2023 and is based on an analysis comparing these 24-month clinical data to a non-concurrent criteria-matched natural history cohort.”

Source: [uniQure press release, FDA RMAT designation (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-receives-fda-regenerative-medicine-advanced-therapy-rmat)

<a id="topic-2.1.1-25"></a>

### Fast Track designation: April 2019

> “April 08, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AMT-130, the Company’s gene therapy candidate for the treatment of Huntington’s disease.”

Source: [uniQure press release, FDA Fast Track designation (2019)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-receives-fda-fast-track-designation-amt-130-gene-therapy)

<a id="topic-2.1.1-26"></a>

### Orphan drug designation: FDA, September 2017

| Field | Quoted record |
| --- | --- |
| Generic name | “adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene” |
| Date designated | “09/27/2017” |
| Orphan designation | “Treatment of Huntington's disease” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “uniQure Biopharma B.V.” |

Source: [FDA orphan drug designation record for AMT-130 (2017)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=525216)

<a id="topic-2.1.1-27"></a>

### Orphan designation: European Commission, January 2018

> “On 17 January 2018, orphan designation (EU/3/17/1957) was granted by the European Commission to uniQure biopharma B.V., the Netherlands, for adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene (also known as AAV5-MiHTT) for the treatment of Huntington's disease.”

Source: [EMA orphan designation EU/3/17/1957 (2018)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1957)

> “We have been granted orphan drug exclusivity for AMT-130 for the treatment of Huntington’s disease subject to the conditions applicable to orphan drug exclusivity in the EU. No pre-marketing authorization orphan designation step is required in the UK, but similar criteria will apply at the time of MA.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.1-28"></a>

### PRIority MEdicines (PRIME) designation

No evidence found.

<a id="topic-2.1.1-29"></a>

### UK marketing authorization application: submitted and validated, third quarter of 2026

> “The Company also announced that its Marketing Authorisation Application (MAA) for ifezuntirgene inilparvovec has been submitted to the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA).”

Source: [uniQure press release, BLA submission (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-submission-biologics-license-application)

> “In the third quarter of 2026, the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) validated the Marketing Authorization Application (MAA) for ifezuntirgene inilparvovec, which was submitted to the MHRA earlier in the quarter.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="topic-2.1.1-30"></a>

### UK MAA timing: third quarter of 2026, April 2026, superseded in September 2026

> “today announced the Company held a Pre-Submission Meeting with the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA) and plans to submit a Marketing Authorization Application (MAA) for AMT-130 for the treatment of Huntington’s disease in the third quarter of 2026.”
> “During the meeting, the Company and MHRA discussed the data package and manufacturing requirements to support a MAA submission for AMT-130.”

Source: [uniQure press release, MHRA pre-submission meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-successful-uk-mhra-pre-submission-meeting-amt)

<a id="topic-2.1.1-31"></a>

### European Union and other markets: statements on regulatory pathways

> “In addition to continuing to partner with the FDA on progressing AMT-130 for the treatment of Huntington’s disease, uniQure plans in parallel to progress discussions with other regulatory agencies, including in the European Union and United Kingdom.”

Source: [uniQure press release, pre-BLA meeting feedback (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-0)

> “The Company is also actively pursuing additional regulatory pathways in international markets for potential registration of AMT-130 and expects to provide further updates in the second half of 2026.”

Source: [uniQure press release, MHRA pre-submission meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-successful-uk-mhra-pre-submission-meeting-amt)

<a id="topic-2.1.1-32"></a>

### Investigational New Drug application effective, January 2019

> “today announced the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for AMT-130, and the IND is now effective allowing uniQure to begin its planned Phase I/II study.”

Source: [uniQure press release, IND clearance (2019)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-clearance-investigational-new-drug)

<a id="topic-2.1.1-33"></a>

### Financing: cash position and runway into 2030, September 2026

> “As of September 30, 2026, we had cash and cash equivalents, restricted cash and investment securities of $770.0 million. We believe these resources will be sufficient to fund our projected operating expenses into 2030, including costs associated with the commercial launches and confirmatory study of ifezuntirgene inilparvovec, ongoing clinical trials of ifezuntirgene inilparvovec, AMT-191 and AMT-260, and potential investments to advance certain pipeline candidates into late-stage development.”
> “We have based our estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect, and as such, we may require additional funding.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.1-34"></a>

### Financing: Hercules term loan terms tied to BLA approval

> “This includes up to $100.0 million in additional availability under our Hercules senior secured term loan facility, which becomes accessible upon BLA approval for ifezuntirgene inilparvovec prior to September 30, 2027, subject to confirmatory trial requirements remaining on track.”
> “The interest-only period will be extended to October 1, 2029 if the BLA for ifezuntirgene inilparvovec is approved prior to October 1, 2028.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.1-35"></a>

### Financing: June 2026 public offering

> “In June 2026, the Company closed an upsized underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, including the full exercise of the underwriters’ option to purchase additional shares. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were $259 million.”

Source: [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and)

<a id="topic-2.1.1-36"></a>

### Cash runway into the second half of 2029, March 2026, superseded in July 2026

> “As of December 31, 2025, the Company had cash, cash equivalents and current investment securities of $622.5 million. The Company expects that cash, cash equivalents and investment securities will be sufficient to fund operations into the second half of 2029.”

Source: [uniQure press release, full year 2025 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2025-financial-results-and-provides-recent)

<a id="topic-2.1.1-37"></a>

### Securities class action

> “On February 10, 2026, a class action complaint captioned Christopher Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was filed against us, certain of our executive officers and another party (collectively, “Defendants”) in the United States District Court for the Southern District of New York.”
> “Lead Plaintiff seeks unspecified damages allegedly caused by purported false and misleading statements and omissions with respect to the import and viability of data from our Phase I/II study of ifezuntirgene inilparvovec and available pathways to regulatory approval. Defendants’ motion to dismiss the amended complaint is currently due November 4, 2026.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
